Endometrial Cancer Market is segmented By Therapeutics (Chemotherapy, Immunotherapy), By End User (Hospitals, Specialty Clinics), By Cancer Stage (Early-Stage Endometrial Cancer, Advanced-Stage Endometrial Cancer), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD Billion) for the above-mentioned segments.
Market Size in USD
CAGR5.7%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.7% |
Market Concentration | High |
Major Players | GlaxoSmithKline Pharmaceuticals, Merck & Co, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics |
The endometrial cancer market is estimated to be valued at USD 26.53 Bn in 2024 and is expected to reach USD 39.10 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031. This robust growth can be attributed to rising incidences of endometrial cancer cases worldwide owing to changing lifestyles and growing geriatric population.